The DEA will start the legal process to reclassify psilocybin from Schedule I (most dangerous, no accepted medical use) to a lower schedule — a historic step that would make it legal to prescribe and manufacture.
EO explicitly directs Attorney General to initiate rescheduling upon Phase 3 completion. COMP360 Phase 3 success is the triggering event. Rescheduling initiation is within executive branch authority — no Congressional action needed. 71% reflects clear direction with DEA institutional resistance risk.